Akt- and MAPK-mediated activation and secretion of MMP-9 into stroma in breast cancer cells upon heregulin treatment

Jin Cho Su, Jung Chae Moon, Bong Kyung Shin, Kyeom Kim Han, Aeree Kim

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Several peptides, such as epidermal growth factor (EGF), heregulin (HRG) and transforming growth factor alpha (TGFα), are ligands for EGFR family. Heregulin beta 1 (HRG-β1) binds to ErbB-3 and -4 and plays important roles in the proliferation and tumorigenesis of breast cancer cells. We investigated proteins through which HRG treatment affects matrix metalloproteinase (MMP)-9 activity. Breast cancer cell lines, including SK-Br3, MCF-7 and MDA-MB-231, were treated with HRG-β1. After 24 h, the activity and expression levels of MMP-9 were increased, but MMP-2 activity was not changed. The increasing rates of MMP-9 activity and expression were most prominent in the SK-Br3 cell line. Upon treatment of SK-Br3 cells with HRG-β1, phosphorylation of Akt was increased showing a peak at 30 min after treatment, and the level decreased after 6 h. The expression levels of Akt were not changed upon HRG-β1 treatment. Phosphorylation of extracellular signal-regulated kinase 1/2 (ERK-1/2), downstream molecules of Akt, was also increased by HRG-β1 treatment. Pretreatment of LY294002, PI3K inhibitor, or PD98059, MAPK inhibitor, partially blocked the heregulin-induced MMP-9 activity. Furthermore, MMP-9 was found to be secreted in human breast cancer tissues. The present results suggest that Akt and MAPK mediate HRG-β1 signaling to MMP-9.

Original languageEnglish
Pages (from-to)83-88
Number of pages6
JournalMolecular Medicine Reports
Volume1
Issue number1
Publication statusPublished - 2008 Dec 1

Fingerprint

Neuregulin-1
Matrix Metalloproteinase 9
Chemical activation
Cells
Breast Neoplasms
Phosphorylation
Cell Line
Transforming Growth Factor alpha
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
Mitogen-Activated Protein Kinase 3
Mitogen-Activated Protein Kinase 1
Matrix Metalloproteinase 2
Phosphatidylinositol 3-Kinases
Epidermal Growth Factor
Carcinogenesis
Tissue
Ligands

Keywords

  • Akt
  • Breast cancer
  • Heregulin
  • MAPK
  • Matrix metalloproteinase-9

ASJC Scopus subject areas

  • Biochemistry
  • Cancer Research
  • Genetics
  • Molecular Biology
  • Molecular Medicine
  • Oncology

Cite this

Akt- and MAPK-mediated activation and secretion of MMP-9 into stroma in breast cancer cells upon heregulin treatment. / Su, Jin Cho; Moon, Jung Chae; Shin, Bong Kyung; Han, Kyeom Kim; Kim, Aeree.

In: Molecular Medicine Reports, Vol. 1, No. 1, 01.12.2008, p. 83-88.

Research output: Contribution to journalArticle

@article{9e6cb114e3574668a63ef27a68700516,
title = "Akt- and MAPK-mediated activation and secretion of MMP-9 into stroma in breast cancer cells upon heregulin treatment",
abstract = "Several peptides, such as epidermal growth factor (EGF), heregulin (HRG) and transforming growth factor alpha (TGFα), are ligands for EGFR family. Heregulin beta 1 (HRG-β1) binds to ErbB-3 and -4 and plays important roles in the proliferation and tumorigenesis of breast cancer cells. We investigated proteins through which HRG treatment affects matrix metalloproteinase (MMP)-9 activity. Breast cancer cell lines, including SK-Br3, MCF-7 and MDA-MB-231, were treated with HRG-β1. After 24 h, the activity and expression levels of MMP-9 were increased, but MMP-2 activity was not changed. The increasing rates of MMP-9 activity and expression were most prominent in the SK-Br3 cell line. Upon treatment of SK-Br3 cells with HRG-β1, phosphorylation of Akt was increased showing a peak at 30 min after treatment, and the level decreased after 6 h. The expression levels of Akt were not changed upon HRG-β1 treatment. Phosphorylation of extracellular signal-regulated kinase 1/2 (ERK-1/2), downstream molecules of Akt, was also increased by HRG-β1 treatment. Pretreatment of LY294002, PI3K inhibitor, or PD98059, MAPK inhibitor, partially blocked the heregulin-induced MMP-9 activity. Furthermore, MMP-9 was found to be secreted in human breast cancer tissues. The present results suggest that Akt and MAPK mediate HRG-β1 signaling to MMP-9.",
keywords = "Akt, Breast cancer, Heregulin, MAPK, Matrix metalloproteinase-9",
author = "Su, {Jin Cho} and Moon, {Jung Chae} and Shin, {Bong Kyung} and Han, {Kyeom Kim} and Aeree Kim",
year = "2008",
month = "12",
day = "1",
language = "English",
volume = "1",
pages = "83--88",
journal = "Molecular Medicine Reports",
issn = "1791-2997",
publisher = "Spandidos Publications",
number = "1",

}

TY - JOUR

T1 - Akt- and MAPK-mediated activation and secretion of MMP-9 into stroma in breast cancer cells upon heregulin treatment

AU - Su, Jin Cho

AU - Moon, Jung Chae

AU - Shin, Bong Kyung

AU - Han, Kyeom Kim

AU - Kim, Aeree

PY - 2008/12/1

Y1 - 2008/12/1

N2 - Several peptides, such as epidermal growth factor (EGF), heregulin (HRG) and transforming growth factor alpha (TGFα), are ligands for EGFR family. Heregulin beta 1 (HRG-β1) binds to ErbB-3 and -4 and plays important roles in the proliferation and tumorigenesis of breast cancer cells. We investigated proteins through which HRG treatment affects matrix metalloproteinase (MMP)-9 activity. Breast cancer cell lines, including SK-Br3, MCF-7 and MDA-MB-231, were treated with HRG-β1. After 24 h, the activity and expression levels of MMP-9 were increased, but MMP-2 activity was not changed. The increasing rates of MMP-9 activity and expression were most prominent in the SK-Br3 cell line. Upon treatment of SK-Br3 cells with HRG-β1, phosphorylation of Akt was increased showing a peak at 30 min after treatment, and the level decreased after 6 h. The expression levels of Akt were not changed upon HRG-β1 treatment. Phosphorylation of extracellular signal-regulated kinase 1/2 (ERK-1/2), downstream molecules of Akt, was also increased by HRG-β1 treatment. Pretreatment of LY294002, PI3K inhibitor, or PD98059, MAPK inhibitor, partially blocked the heregulin-induced MMP-9 activity. Furthermore, MMP-9 was found to be secreted in human breast cancer tissues. The present results suggest that Akt and MAPK mediate HRG-β1 signaling to MMP-9.

AB - Several peptides, such as epidermal growth factor (EGF), heregulin (HRG) and transforming growth factor alpha (TGFα), are ligands for EGFR family. Heregulin beta 1 (HRG-β1) binds to ErbB-3 and -4 and plays important roles in the proliferation and tumorigenesis of breast cancer cells. We investigated proteins through which HRG treatment affects matrix metalloproteinase (MMP)-9 activity. Breast cancer cell lines, including SK-Br3, MCF-7 and MDA-MB-231, were treated with HRG-β1. After 24 h, the activity and expression levels of MMP-9 were increased, but MMP-2 activity was not changed. The increasing rates of MMP-9 activity and expression were most prominent in the SK-Br3 cell line. Upon treatment of SK-Br3 cells with HRG-β1, phosphorylation of Akt was increased showing a peak at 30 min after treatment, and the level decreased after 6 h. The expression levels of Akt were not changed upon HRG-β1 treatment. Phosphorylation of extracellular signal-regulated kinase 1/2 (ERK-1/2), downstream molecules of Akt, was also increased by HRG-β1 treatment. Pretreatment of LY294002, PI3K inhibitor, or PD98059, MAPK inhibitor, partially blocked the heregulin-induced MMP-9 activity. Furthermore, MMP-9 was found to be secreted in human breast cancer tissues. The present results suggest that Akt and MAPK mediate HRG-β1 signaling to MMP-9.

KW - Akt

KW - Breast cancer

KW - Heregulin

KW - MAPK

KW - Matrix metalloproteinase-9

UR - http://www.scopus.com/inward/record.url?scp=69249097943&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69249097943&partnerID=8YFLogxK

M3 - Article

C2 - 21479382

AN - SCOPUS:69249097943

VL - 1

SP - 83

EP - 88

JO - Molecular Medicine Reports

JF - Molecular Medicine Reports

SN - 1791-2997

IS - 1

ER -